ALSO READGoldman Sachs raises $7 billion for new private equity fund -sources Goldman Sachs raises $7 billion for new private equity fund - sources Providence sells entire 3.3% stake in Idea for Rs 1,288-cr Goldman Sachs announces India Impact Fund winners Goldman Sachs misses estimates on weak trading, shares drop
Eris Lifesciences today mopped up Rs 779 crore from 21 anchor investors, including Abu Dhabi Investment Authority and Goldman Sachs.
Ahead of its initial public offer starting tomorrow, the company has allotted 1.29 crore shares at a price of Rs 603 apiece.
The price band for the share sale has been fixed at Rs 600-603.
According to a filing by the company to the exchanges, it has raised Rs 779.43 crore by allotting shares to 21 anchor investors.
The anchor investors include Abu Dhabi Investment Authority - Behave, Goldman Sachs India, Morgan Stanley India Investment Fund Inc, SBI Magnum Balanced Fund, FIL Investments (Mauritius) Ltd, Merrill Lynch Markets Singapore Pte Ltd and IDFC Premier Equity Fund.
The offer, which closes on June 20, comprises sale of 2.89 crore shares.
The book Running Lead Managers to the offer are Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India).
Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)